IKENA ONCOLOGY INC (IKNA)

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning!

UPDATE – Ikena Oncology Announces Strategic Update

UPDATE – Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date ...

Ikena Oncology Announces Strategic Update

Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date ...

IKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024

IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the first quarter of 2024.

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program...

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in...

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024...

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in...

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr....

Ikena to cut 35% of workforce, extend cash runway into 2H 2026 (NASDAQ:IKNA)

Ikena Oncology (IKNA) plans to cut its workforce by 35% to focus on its two lead drug programs, which will extend its cash runway into 2H 2026. Read more here.

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety...

Thursday Sector Laggards: Biotechnology, Drugs

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without...